All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual Abstract | Venetoclax plus azacitidine for patients with IDH1/2 mutated AML who are ineligible for intensive chemotherapy
The AML Hub is delighted to present a visual abstract representing key data pooled from the phase III Viale-a trial (NCT02993523) and a phase Ib trial (NCT02203773) investigating the efficacy and safety of venetoclax plus azacitidine and azacitidine monotherapy in treatment-naïve patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. This analysis will focus on isocitrate dehydrogenase (IDH) 1/2 mutational status; however, an overview of the Viale-a trial has been previously reported by the AML Hub, as well as articles on MRD response and TP53 mutational status.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox